Survival in patients with recurrent Glioblastoma
The calculator implements the EORTC Scoring System for recurrent Glioblastoma as published in the paper:
Thierry Gorlia, Roger Stupp, Alba. A. Brandes, Roy. R. Rampling, Pierre Fumoleau, Christian Dittrich, Mario M.Campone , Chris. C. Twelves, Eric.Raymond, Monika E. Hegi, Denis.Lacombe, Martin J. van den Bent. New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials (Eur J Cancer 2012;48:1176-1184).
It allows the user to estimate the median progression-free survival, median survival , probability of progression-free survival at six months, the probability of survival at one year in patients treated with chemoradiation with temozolomide at first diagnosis and whose disease recurs or progresses. It is built on four different important prognostic factors at this stage of the disease: need for corticosteroids at baseline, WHO Performance Status, number of target lesions, and maximum diameter of the largest target lesion.
Survival in newly diagnosed Glioblastoma
The provided programs implements the EORTC Scoring System for newly diagnosed Glioblastoma as published in the paper: Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3 (Lancet Oncol. 2007 Dec 12). They allow the user to estimate the median survival and the probability of survival at 2 years in patients with newly diagnosed Glioblastoma based on 7different prognostic factors: Therapy administered, Age, Extent of surgery, Mini Mental Score Examination, Administration of corticosteroids, WHO Performance Status, MGMT promoter methylation status.
Recurrence and Progression in Stage Ta T1 Bladder Cancer (update for iPhone / iPad and Androïd)
The provided software implements the EORTC Scoring System and Risk Tables for Stage Ta T1 Bladder Cancer as published in the paper:
Sylvester RJ, van der Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DWW, and Kurth KH. Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials (European Urology 49: 466 – 477, 2006). They allow the user to estimate the probability of recurrence and progression in patients with stage Ta T1 bladder cancer based on six different factors:
Toxicity in imatinib treated GIST patients
The provided software implements the risk models published in the paper: Martine Van Glabbeke, Jaap Verweij, Paolo G. Casali, John Simes, Axel Le Cesne, Peter Reichard, Rolf Issels, Ian R. Judson, Allan T. van Oosterom, Jean-Yves Blay. Predicting toxicities for patients with advanced gastro-intestinal stromal tumors (GIST) treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sacoma Group and the Australian Gastro-Intestinal Trials Group (European Journal of Cancer 42 (2006) 2277-2285). It allows the user to estimate the probability of experiencing edema (CTC grade 2+), lethargy (CTC grade 2+), skin rash (CTC grade 2+), nausea (CTC grade 2+), diarrhea (CTC grade 2+), anemia(CTC grade 3+) neutropenia (CTC grade 3+) for individual GIST patients treated with imatinib mesylate, at doses ranging from 400 mg/day to 800 mg/day. Estimations are based on the intended daily dose and 8 factors: Age, Sex, Performance status at treatment start, Prior chemotherapy (N/Y), Largest diameter of the largest lesion, Identified gastro-intestinal origin of the tumor (N/Y), Hemoglobin level at treatment start, Neutrophil count at treatment start